Pete completed an MChem (2009) and PhD (2013) at Durham University, with his doctoral studies focusing on the development of paramagnetic chemical shift (PARASHIFT) agents for new magnetic resonance imaging and spectroscopy (MRI/MRS) applications. Following his PhD, he was awarded an EPSRC Doctoral Prize Fellowship to move to The University of Manchester to work on biosensors based on the interaction between flavoeznymes and luminescent upconverting nanoparticles. In 2015, Pete was awarded a Wellcome Trust-MIT Postdoctoral Fellowship and moved to the Biological Engineering Department at the Massachusetts Institute of Technology. Here, he focused on tools for molecular functional MRI, including contrast agents capable of reporting on neurotransmitters and strategies to improve delivery of agents across the blood-brain barrier (BBB).
Research in Pete's group spans across multiple Schools, with dedicated lab and office space across the Schools of Chemistry and Medicine. Pete's background is in developing molecular tools for imaging and sensing applications, with a particular focus on contrast agents for magnetic resonance imaging (MRI). His work has included new methods for imaging contrast agents in vivo (19F/1H PARASHIFT MRI/MRS), novel forms of contrast agents (metal-free contrast, functional agents), sensors based on a luminescence readout, and strategies for increasing delivery of agents across the blood-brain barrier (BBB). His lab experience began with a background in synthetic chemistry and expanded to cover molecular biology, histology, and preclinical imaging.
Now based across the Precision Imaging Beacon within the School of Medicine and with lab space and research ongoing in the School of Chemistry, Pete is using his broad background experience to focus on neurodegenerative disease. He is approaching this challenging problem from a multi-angle approach; new imaging methods for improving sensitivity or specificity, novel contrast agents for targeted and/or functional imaging, and understanding and improving trans-BBB delivery in healthy and disease models. While primarily focused on imaging, some of the work also has significant overlap in therapeutic and theranostic applications.
BRICAULT, SARAH, BARANDOV, ALI, HARVEY, PETER, DETIENNE, ELIZABETH, HAI, AVIAD and JASANOFF, ALAN, 2020. Image-guided neural activity manipulation with a paramagnetic drug. Nature communications. 11(1), 136 SEDGWICK, ADAM C., BREWSTER, JAMES T., II, HARVEY, PETER, IOVAN, DIANA A., SMITH, GRAHAM, HE, XIAO-PENG, TIAN, HE, SESSLER, JONATHAN L. and JAMES, TONY D., 2020. Metal-based imaging agents: progress towards interrogating neurodegenerative disease CHEMICAL SOCIETY REVIEWS. 49(10), 2886-2915 NGUYEN, HUNG V-T, DETAPPE, ALEXANDRE, HARVEY, PETER, GALLAGHER, NOLAN, MATHIEU, CLELIA, AGIUS, MICHAEL P., ZAVIDIJ, OKSANA, WANG, WENCONG, JIANG, YIVAN, RAJCA, ANDRZEJ, JASANOFF, ALAN, GHOBRIAL, IRENE M., GHOROGHCHIAN, P. PETER and JOHNSON, JEREMIAH A., 2020. Pro-organic radical contrast agents ("pro-ORCAs") for real-time MRI of pro-drug activation in biological systems POLYMER CHEMISTRY. 11(29), 4768-4779
BREWSTER, JAMES T., II, THIABAUD, GREGORY D., HARVEY, PETER, ZAFAR, HADIQA, REUTHER, JAMES F., DELL'ACQUA, SIMONE, JOHNSON, RACHEL M., ROOT, HARRISON D., METOLA, PEDRO, JASANOFF, ALAN, CASELLA, LUIGI and SESSLER, JONATHAN L., 2020. Metallotexaphyrins as MRI-Active Catalytic Antioxidants for Neurodegenerative Disease: A Study on Alzheimer's Disease CHEM. 6(3), 703-724